Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is an open, blank controlled clinical trial to evaluate the efficacy and safety of SA58
nasal spray in the prevention COVID-19 infection among health care workers at high risk of
SARS-CoV-2 infection.